Therapy with transcutaneous administration of imiquimod combined with oral administration of sorafenib suppresses renal cell carcinoma growing in an orthotopic mouse model

Imiquimod is an imidazoquinoline immune response modifier that is used in antiviral and antiallergic creams. Combination therapy using transcutaneous imiquimod and oral sorafenib was previously demonstrated to reduce the tumor burden of renal cell carcinoma growing cutaneously in a mouse model. In t...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncol Lett
Hlavní autoři: Karashima, Takashi, Udaka, Keiko, Niimura, Mayumi, Suzuki, Katsuhide, Osakabe, Hiroto, Shimamoto, Tsutomu, Fukata, Satoshi, Inoue, Keiji, Kuroda, Naoto, Seiki, Motoharu, Shuin, Taro
Médium: Artigo
Jazyk:Inglês
Vydáno: D.A. Spandidos 2017
Témata:
Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5494610/
https://ncbi.nlm.nih.gov/pubmed/28693290
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2017.6235
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky